Guardant360 CDx provides complete genotyping in advanced colorectal cancer for guideline-recommended biomarkers, including MSI, expanded KRAS/NRAS and BRAF.
A recent study* showed that only 40% of advanced colon cancer patients received guideline-recommended testing to help determine therapy options.
* Gutierrez et.al 2019 JCO Precision Onc. https://ascopubs.org/doi/full/10.1200/PO.19.00274
Questions about Guardant360 CDx?
Call 855.698.8887 or email [email protected]